St. John’s Wort Interactions: Drugs, Risks, and Safety Guide

If you’re considering this popular herb for mood support, you’ve likely wondered about st john's wort interactions. This matters: St. John’s wort (Hypericum perforatum) can change how many prescription medicines work—sometimes making them less effective and sometimes increasing side effects. This guide explains how it interacts, which drug classes are most affected, what symptoms to watch for, and practical steps to stay safe.

What is St. John’s Wort? Brief overview and common uses

• Botanical: Hypericum perforatum; commonly standardized to hypericin or hyperforin content
• Traditional use: For centuries in European herbal medicine for “nervousness,” low mood, and wound care (traditional evidence)
• Modern use: Mild to moderate depressive symptoms, menopausal symptoms, and somatic anxiety (moderate evidence for mood in some meta-analyses). It is available as teas, tinctures, and tablets/capsules.

What the Research Says

• Mood: Multiple randomized trials and meta-analyses suggest St. John’s wort extracts can improve mild to moderate depressive symptoms compared with placebo and with similar efficacy to some SSRIs, with fewer adverse effects in select studies (moderate evidence). However, quality and standardization vary.
• Safety headline: Interactions are the major safety concern; these are well documented across pharmacokinetic studies, case reports, and regulatory advisories (strong evidence).

How St. John’s Wort works: CYP enzymes, P‑glycoprotein, and serotonin effects

St. John’s wort influences both drug metabolism and brain chemistry. Understanding these mechanisms explains most interactions.

• Cytochrome P450 enzymes (CYPs): Its constituent hyperforin activates the pregnane X receptor (PXR), which increases transcription of drug‑metabolizing enzymes—especially CYP3A4, and to a lesser extent CYP2C9 and CYP2C19. Result: Many drugs are cleared faster, lowering their blood levels and effectiveness (strong evidence from human pharmacokinetic studies).
• P‑glycoprotein (P‑gp): Hyperforin also induces the efflux transporter P‑gp (ABCB1) in the gut, liver, kidneys, and blood–brain barrier. This can reduce absorption and tissue concentrations of P‑gp substrates like digoxin and certain chemotherapy and anticoagulant drugs (strong evidence).
• Serotonin and other neurotransmitters: St. John’s wort inhibits the reuptake of serotonin (and to a lesser extent norepinephrine and dopamine) and may modulate TRPC6 channels. In vitro MAO inhibition has been reported but appears weak at typical doses. Result: When combined with other serotonergic agents, there is a risk of serotonin syndrome (moderate evidence clinically, strong mechanistic rationale).

Important nuances

• Time course: Enzyme/transporter induction ramps up over 3–7 days, often peaking by ~2 weeks; it can persist for about 1–2 weeks after stopping. Pharmacodynamic serotonergic effects begin sooner.
• Hyperforin content: High‑hyperforin extracts drive most pharmacokinetic interactions. Low‑hyperforin products may have fewer interactions but may also be less effective; clinical data are limited (emerging evidence).
• Product variability: Over‑the‑counter products vary in hyperforin/hypericin content, leading to unpredictable interaction magnitude.

St. John’s Wort Interactions by drug class

Below are major interaction categories, their likely mechanisms, and practical implications.

Antidepressants (SSRIs, SNRIs, MAOIs, TCAs, others)

• Mechanism: Additive serotonergic effects; some metabolic induction possible.
• Examples: Sertraline, fluoxetine, paroxetine, citalopram/escitalopram; venlafaxine, duloxetine; MAOIs (phenelzine, tranylcypromine); TCAs; mirtazapine; trazodone; bupropion (not serotonergic but interactions possible via metabolism); buspirone; linezolid and methylene blue (MAOI‑like antibiotics/dyes).
• Clinical concern: Serotonin syndrome—especially with SSRIs/SNRIs/MAOIs, linezolid, or triptans/tramadol. Symptoms can develop within hours to days (moderate evidence clinically, strong mechanistic rationale). Some antidepressant levels may decrease due to induction, potentially reducing effect.
• Guidance: Avoid combining with other serotonergic antidepressants or MAOIs. If switching, allow washout guided by a clinician. Seek urgent care if serotonin syndrome signs occur (see below).

Oral contraceptives and hormone therapies

• Mechanism: Induction of CYP3A4 and P‑gp lowers ethinyl estradiol and progestin levels.
• Clinical concern: Breakthrough bleeding, contraceptive failure, unintended pregnancy (moderate to strong evidence including pharmacokinetic studies, case reports, and regulatory advisories). Similar concerns may apply to oral estrogen or testosterone therapies.
• Guidance: Avoid concurrent use with combined or progestin‑only oral contraceptives, transdermal patches, implants, vaginal rings, and emergency contraceptive pills that rely on CYP3A4 metabolism. If use cannot be avoided, add a barrier method during use and for at least 2 weeks after stopping St. John’s wort, and discuss alternative contraception with your clinician.

Anticoagulants (warfarin) and antiplatelets; direct oral anticoagulants (DOACs)

• Warfarin
  • Mechanism: Induction of CYP2C9 and CYP3A4 increases warfarin clearance.
  • Clinical concern: Decreased INR, loss of anticoagulation, thrombosis risk (moderate evidence: case reports and pharmacokinetic changes).
  • Guidance: Generally avoid. If used, very close INR monitoring and dose adjustments are required under clinician supervision.
• DOACs (apixaban, rivaroxaban, edoxaban, dabigatran)
  • Mechanism: Induction of CYP3A4 and/or P‑gp lowers exposure for apixaban/rivaroxaban (CYP3A4 and P‑gp substrates) and dabigatran/edoxaban (P‑gp substrates).
  • Clinical concern: Reduced anticoagulant effect and clot risk (moderate evidence; labeling warns against strong inducers like St. John’s wort).
  • Guidance: Avoid concomitant use.
• Antiplatelets (clopidogrel, prasugrel, ticagrelor)
  • Mechanism: Complex. Induction may increase activation of prodrugs (clopidogrel, prasugrel) but decrease levels of ticagrelor (CYP3A4 substrate).
  • Clinical concern: Potentially increased bleeding with clopidogrel or reduced effect with ticagrelor (limited, mixed evidence; emerging to moderate).
  • Guidance: Avoid or consult cardiology/pharmacy for individualized assessment.

HIV antiretrovirals and hepatitis antivirals

• Mechanism: Strong induction of CYP3A4 and P‑gp markedly lowers levels of many protease inhibitors (PIs), non‑nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, and hepatitis C direct‑acting antivirals (DAAs).
• Clinical concern: Virologic failure, resistance, hepatitis treatment failure (strong evidence; clinical pharmacokinetic studies and regulatory contraindications). A landmark NEJM study showed substantial reductions in indinavir levels with St. John’s wort.
• Guidance: Contraindicated. Do not combine. Use trusted interaction checkers and follow HIV/hepatitis guidelines.

Immunosuppressants (cyclosporine, tacrolimus, sirolimus)

• Mechanism: CYP3A4 and P‑gp induction.
• Clinical concern: Subtherapeutic drug levels, transplant rejection (strong evidence with multiple case reports/series and regulatory warnings).
• Guidance: Contraindicated. Transplant teams uniformly advise against use.

Chemotherapy and targeted agents

• Mechanism: Induction of CYP3A4 and P‑gp can reduce exposure to many agents (e.g., irinotecan, imatinib, dasatinib, nilotinib, etoposide, docetaxel, vincristine), though sensitivity varies by drug.
• Clinical concern: Reduced treatment efficacy or altered toxicity (moderate evidence; oncology guidelines generally advise avoidance of St. John’s wort during chemotherapy and targeted therapy).
• Guidance: Avoid unless your oncology team explicitly clears a product.

Other common medicines

• Statins: Simvastatin and atorvastatin (CYP3A4 substrates) may have reduced levels; rosuvastatin and pravastatin less affected (moderate evidence). Clinical concern: Loss of LDL‑lowering effect.
• Digoxin: As a P‑gp substrate, levels can drop with St. John’s wort (strong evidence from PK studies). Clinical concern: Loss of rate control or heart failure symptom worsening.
• Benzodiazepines: Midazolam, triazolam, alprazolam (CYP3A4 substrates) may have reduced sedative effects (moderate evidence).
• Antiepileptics: Complex bidirectional interactions; St. John’s wort may reduce levels of some agents and could lower seizure threshold in rare cases. Specialist input advised (emerging to moderate evidence).
• Opioids and pain meds: Oxycodone/fentanyl (CYP3A4 substrates) may have reduced effect; tramadol adds serotonergic risk (moderate evidence mechanistic, limited clinical data).
• Thyroid meds: No robust evidence of a direct interaction with levothyroxine, but mood/energy changes from drug level shifts can confound monitoring (limited evidence).
• Respiratory meds: Some inhaled or oral corticosteroids (budesonide, fluticasone) are CYP3A4 substrates; induction could reduce effect (emerging to moderate evidence).

Signs and symptoms of clinically important interactions—and when to seek help

Recognizing interaction red flags can prevent harm.

• Serotonin syndrome (urgent): Agitation, restlessness, confusion, rapid heartbeat, high blood pressure, dilated pupils, sweating, tremor, muscle rigidity, diarrhea, fever. Call emergency services if severe (e.g., high fever, confusion, seizures).
• Loss of efficacy (urgent depending on condition):
  • Birth control: Breakthrough bleeding, missed periods, pregnancy symptoms.
  • Anticoagulants: Sudden leg swelling or pain, chest pain, shortness of breath, neurological deficits (possible clot).
  • HIV/hepatitis meds: Rising viral load (lab), new or worsening symptoms per your care team.
  • Transplant meds: Signs of rejection (fever, graft tenderness, reduced organ function—e.g., rising creatinine for kidney transplant).
  • Heart meds: Worsening heart rate control, increased blood pressure, more angina, or heart failure symptoms.
• Increased side effects/bleeding:
  • Easy bruising, nosebleeds, black or tarry stools, vomiting blood, severe headache (seek urgent care).
  • Excess sedation changes or paradoxical symptoms with CNS drugs.

Who is at higher risk?

• Dose and product variability: High‑hyperforin extracts and higher daily doses raise interaction risk. Over‑the‑counter products vary widely in active content.
• Polypharmacy and chronic illness: Older adults, those with multiple medications, and people with liver or kidney disease.
• Specific groups: Transplant recipients, people living with HIV or chronic hepatitis on antivirals, those on warfarin/DOACs, patients on chemotherapy, and people using hormonal contraception.
• Pregnancy and breastfeeding: Safety is not well established; avoid unless a clinician advises otherwise. Interaction risks to pregnancy planning and contraception are significant.
• Mental health considerations: History of bipolar disorder or mania—St. John’s wort may precipitate mood switching (emerging to moderate evidence).

Practical safety steps

• Talk to your clinician or pharmacist before starting St. John’s wort—especially if you take prescription meds. Bring the product label if possible.
• Create a complete medication and supplement list and keep it updated. Share it at every visit. See our Medication List Template.
• Lab and level monitoring:
  • Warfarin: Check INR more frequently when starting/stopping St. John’s wort.
  • Transplant/HIV/hepatitis: Follow drug level and viral load protocols; never start St. John’s wort without specialist approval.
  • Other narrow‑therapeutic‑index drugs (digoxin, some antiarrhythmics, antiepileptics): Consider level checks when starting/stopping.
• Before surgery: Because enzyme/transporter induction can persist, consider stopping St. John’s wort 1–2 weeks before elective surgery or anesthesia unless your clinician advises otherwise. See Preparing for Surgery and Supplements.
• Consider safer alternatives for mood support if you take interacting medications:
  • Non‑pharmacologic: Cognitive‑behavioral therapy, mindfulness‑based stress reduction, regular exercise, sleep optimization, social connection, light therapy for seasonal patterns. See our Sleep and Mood Toolkit.
  • Nutritional strategies: Address deficiencies (e.g., vitamin D, B12, iron) based on labs; discuss omega‑3s with your clinician if you’re not on blood thinners.
• Product selection if appropriate: If your clinician agrees St. John’s wort is reasonable, consider standardized products with clearly labeled hyperforin content and third‑party testing (USP, NSF) to limit variability. Note: Even standardized products can interact; “low‑hyperforin” formulations may reduce but do not eliminate risk.

What the Research Says: Key evidence snapshots

• Enzyme/transporter induction: Human studies show St. John’s wort (hyperforin‑rich extracts) induces CYP3A4 and P‑gp, reducing exposure to substrates like midazolam and digoxin (strong evidence).
• HIV antiretrovirals: A controlled trial demonstrated a marked reduction in indinavir plasma levels with St. John’s wort; regulators contraindicate co‑use (strong evidence).
• Immunosuppressants: Multiple case reports/series link St. John’s wort to reduced cyclosporine/tacrolimus levels and transplant rejection (strong evidence).
• Oral contraceptives: Pharmacokinetic studies and post‑marketing reports show decreased hormone levels, breakthrough bleeding, and unintended pregnancies (moderate to strong evidence). Safety advisories exist in the US, EU, and UK.
• Anticoagulants: Reports of decreased INR with warfarin and labeling cautions for DOACs with strong inducers (moderate evidence).
• Oncology: Pharmacokinetic data and expert guidance recommend avoiding St. John’s wort with many chemotherapy and targeted agents (moderate evidence).

How to check interactions: trusted resources and tools

Use multiple, reliable sources and, when possible, consult a pharmacist.

• Professional databases: Lexicomp, Micromedex, Natural Medicines (subscription; robust monographs).
• Government and academic resources:
  • NIH Office of Dietary Supplements and NCCIH monographs on St. John’s wort
  • FDA and EMA/MHRA safety communications regarding herb–drug interactions
  • University of Liverpool HIV and HEP drug interaction checkers
• Consumer tools: Medscape, Drugs.com, and other interaction checkers can be starting points but may not capture all nuances.
• Primary literature: Pharmacokinetic trials (e.g., indinavir–St. John’s wort), case reports (cyclosporine rejection), and contraceptive studies offer mechanistic and clinical details.
• On GoldBamboo: Herb–Drug Interactions Guide, Serotonin Syndrome, Warfarin and INR Monitoring, HIV Medications Overview, Cancer Treatment and Supplements.

Quick FAQs

• Can I take St. John’s wort with my birth control?

  • Not recommended. St. John’s wort can lower hormone levels and reduce contraceptive effectiveness. If exposed, use backup contraception during use and for at least 2 weeks after stopping, and consult your clinician about alternatives. See Contraception Options.

• How long should I separate St. John’s wort from other medicines?

  • Spacing doses does not prevent enzyme/transporter induction. If an interaction is expected, avoidance—not timing—is needed.

• If I stop St. John’s wort, how long until interactions wear off?

  • Induction usually diminishes over 1–2 weeks after stopping, but the exact time varies. Your clinician may adjust medication doses and monitoring during this period.

• Are topical St. John’s wort products (oils/creams) safer?

  • Topicals are less likely to cause systemic interactions but can still cause photosensitivity. Do not assume they’re interaction‑free—discuss with your clinician.

• Is a “low‑hyperforin” extract a safe workaround?

  • Lower hyperforin content likely reduces induction, but not all products are consistent, and clinical efficacy and safety data are limited. Use only with clinician guidance.

• Can I combine St. John’s wort with SSRIs if I feel better on both?

  • Combining increases serotonin syndrome risk and is generally discouraged. Speak with your prescriber about a monitored switch if appropriate.

• Does St. John’s wort cause bleeding?

  • It doesn’t directly thin blood, but by altering levels of anticoagulants/antiplatelets, it can increase bleeding or clotting risk. Monitor for bleeding signs and consult your clinician.

Practical takeaways

• St john's wort interactions are primarily due to strong induction of CYP3A4/P‑gp and additive serotonergic effects.
• Avoid St. John’s wort with: HIV/hepatitis antivirals, transplant immunosuppressants, warfarin/DOACs, most chemotherapy/targeted cancer agents, and hormonal contraception.
• Work closely with your clinician or pharmacist; do not start or stop St. John’s wort without professional input if you take prescription medications.
• Watch for red flags: serotonin syndrome, bleeding, clot symptoms, breakthrough bleeding, or return of disease symptoms.
• Use trusted interaction checkers and keep all your providers informed about supplements.

Disclaimer

This content is for educational purposes and does not replace personalized medical advice. Always consult your healthcare professional before starting, stopping, or combining herbs and medications, especially if you have chronic conditions, are pregnant or breastfeeding, or take prescription drugs.